Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12679296 | 0.76 | KDM4E (0.32) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| SCHEMBL13054915 | 0.75 | TSHR (0.38) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| SCHEMBL23423259 | 0.73 | TSHR (0.45) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| SCHEMBL19426510 | 0.69 | LMNA (0.48) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| SCHEMBL13081612 | 0.69 | TSHR (0.50) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| SCHEMBL12409772 | 0.67 | TOP2A (0.31) | TOP2ATOP2BALDH1A1MAPTTDP1 | |
| SCHEMBL18136433 | 0.65 | TSHR (0.42) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| SCHEMBL83878 | 0.65 | — | — | |
| SCHEMBL14359632 | 0.64 | TSHR (0.61) | TSHRNPSR1KDM4ELMNACYP2C19 | |
| SCHEMBL13805603 | 0.64 | TSHR (0.44) | TSHRNPSR1KDM4ELMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20170283434-A1 | NK1 ANTAGONISTS | OPKO HEALTH INC (US) | 2017-10-05 | — | — | US | disclosed |
| US-9688693-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688693-B2 | NK1 antagonists | OPKO HEALTH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20140336158-A1 | NK1 ANTAGONISTS | TERSERA THERAPEUTICS LLC | 2014-11-13 | — | — | US | disclosed |
| US-8883889-B2 | Pigment compositions comprising pyrrolo[3,4-c]pyrroles | BASF SE (DE) | 2014-11-11 | — | — | US | disclosed |
| EP-2055748-B1 | HIGH-CHROMA C.I. PIGMENT RED 254 AND PROCESS FOR PRODUCING THE SAME | DAINIPPON INK & CHEMICALS (JP) | 2013-04-17 | — | — | EP | disclosed |
| CN-1553913-B | Process for the direct preparation of pyrrolo [3,4-c]pyrroles | CIBA SC HOLDING AG | 2011-10-05 | — | — | CN | disclosed |
| US-7837784-B2 | High-chroma C.I. Pigment Red 254 and process for producing the same | DIC CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20090241802-A1 | HIGH-CHROMA C.I. PIGMENT RED 254 AND PROCESS FOR PRODUCING THE SAME | DIC CORPORATION (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20070117889-A1 | Process for the direct preparation of pyrrolo[3,4-C]pyrroles | RUFFIEUX VINCENT | 2007-05-24 | — | — | US | disclosed |
| EP-1425282-B1 | PROCESS FOR THE PREPARATION OF DIKETOPYRROLOPYRROLES | CIBA SC HOLDING AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| US-7186847-B2 | From a pyrrolidinone compound; coloring high molecular weight material | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20040249162-A1 | From a pyrrolidinone compound; coloring high molecular weight material | BASF SE (DE) | 2004-12-09 | — | — | US | disclosed |
| CN-1553913-A | Process for the direct preparation of pyrrolo [3,4-c]pyrroles | �������⻯ѧƷ�ع�����˾ | 2004-12-08 | — | — | CN | disclosed |
| US-20040171847-A1 | From a pyrrolidinone compound; coloring high molecular weight material | CIBA SPECIALTY CHEMICALS CORP. | 2004-09-02 | — | — | US | disclosed |
| EP-1436296-A2 | PROCESS FOR THE DIRECT PREPARATION OF PYRROLO 3,4-C]PYRROLES | Ciba SC Holding AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| EP-1425282-A2 | PROCESS FOR THE PREPARATION OF DIKETOPYRROLOPYRROLES | Ciba SC Holding AG (CH) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022848-A2 | PROCESS FOR THE PREPARATION OF DIKETOPYRROLOPYRROLES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022847-A2 | PROCESS FOR THE DIRECT PREPARATION OF PYRROLO[3,4-C]PYRROLES | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283434-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | TSHR 165/4885NPSR1 61/4885KDM4E 3252/4885 |
| US-20240208941-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | TSHR 2777/4885NPSR1 4442/4885KDM4E 1981/4885 |
| US-20140336158-A1 | NK1 ANTAGONISTS | HRH4, CRHR2, HRH2 | TSHR 165/4885NPSR1 61/4885KDM4E 3252/4885 |
| US-20040249162-A1 | From a pyrrolidinone compound; coloring high molecular weight material | PAXBP1, PAX3, PPOX | TSHR 3483/4885NPSR1 685/4885KDM4E 392/4885 |
| US-20070117889-A1 | Process for the direct preparation of pyrrolo[3,4-C]pyrroles | PAX3, PPOX, FIP1L1 | TSHR 4041/4885NPSR1 1283/4885KDM4E 333/4885 |
| US-20040171847-A1 | From a pyrrolidinone compound; coloring high molecular weight material | MKI67, PAH, PKLR | TSHR 1100/4885NPSR1 760/4885KDM4E 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.